TMI-1

N/A

Report date: 2022/07/01 15:29:28

NME

Base Information

Drug NameTMI-1

Drug Alias NameTMI-1

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionDisintegrin and metalloproteinase domain-containing protein 17 inhibitors

TargetsDisintegrin and metalloproteinase domain-containing protein 17

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

ATC CodeN/A